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Abstract: More than 130 million people worldwide chronically
infected with hepatitis C virus (HCV) are at risk of developing severe
liver disease. Antiviral treatments are only partially effective against
HCV infection, and a vaccine is not available. Development of more
efﬁcient therapies has been hampered by the lack of a small animal
model. Building on the observation that CD81 and occludin (OCLN)
comprise the minimal set of human factors required to render mouse
cells permissive to HCV entry, we previously showed that transient
expression of these two human genes is sufﬁcient to allow viral
uptake into fully immunocompetent inbred mice. Here we demon-
strate that transgenic mice stably expressing human CD81 and OCLN
also support HCV entry, but innate and adaptive immune responses
restrict HCV infection in vivo. Blunting antiviral immunity in genet-
ically humanized mice infected with HCV results in measurable
viraemia over several weeks. In mice lacking the essential cellular
co-factor cyclophilin A (CypA), HCV RNA replication is markedly
diminished, providing genetic evidence that this process is faithfully
recapitulated. Using a cell-based ﬂuorescent reporter activated by
the NS3-4A protease we visualize HCV infection in single hepatocytes
in vivo. Persistently infected mice produce de novo infectious
particles, which can be inhibited with directly acting antiviral drug
treatment, thereby providing evidence for the completion of the
entire HCV life cycle in inbred mice. This genetically humanized
mouse model opens new opportunities to dissect genetically HCVJournal of Hepatology 20
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The narrow tropism of hepatitis C virus (HCV) for human and
non-human primate hepatocytes hampers the development of a
robust small animal model to study HCV infection. Recently
developed mouse models [1–4] are based on human liver-chi-
meric immunodeﬁcient mice or genetically humanized immu-
nocompetent mice. Although valuable to assess deﬁned
aspects of HCV infection, none of these models allows studying
the complex HCV–host interactions globally, given the lack of a
functional immune system or of robust HCV replication and
viremia.
Within the past years, our understanding on the species-
speciﬁc restrictions of HCV infection has steadily advanced.
While mouse hepatocytes can assemble and release infectious
virions, the HCV life cycle is restricted at the steps of entry
and replication. The identiﬁcation of CD81 and occludin (OCLN)
as the minimal human entry factors required to overcome the
restriction of HCV entry into mouse hepatocytes [3] was a ﬁrst
breakthrough towards the development of humanized immu-
nocompetent mice to study HCV infection. This and the obser-
vation that HCV RNA replicates more efﬁciently in mouse cells
lacking antiviral signaling [5,6] provided the framework to reca-
pitulate the entire HCV life cycle in mouse cells in vitro using a
series of mice with defects in antiviral immunity [7–9]. Indeed,
blunting pathways involving MAVS, RIG-I, IRF3, IRF9, IFN-ab
receptor, PKR or STAT1 increased HCV replication [7–9].
Enhanced HCV replication was also observed following type I
IFN-neutralization in IRF5-, IRF7-, IRF1-, and PKR-knock-out
cells [9].
A team led by Alexander Ploss and Charles M. Rice at Rocke-
feller University, New York, USA now developed new mice to
recapitulate the HCV life cycle in vivo [10]. The authors ﬁrst cre-
ated HCV entry-permissive transgenic mice expressing the four
main human entry factors (4hEF) of HCV – CD81, claudin-1
(CLDN1), scavenger receptor BI (SR-BI), and OCLN in the liver.
HCV RNA slightly and transiently increased in the serum and
the liver of these mice upon infection with cell culture-derived
HCV (HCVcc) and viral clearance was associated with strong
innate immune responses. These mice were then crossed with
mouse strains deﬁcient in genes involved in innate immunity.
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Fig. 1. A novel mouse model recapitulating the entire HCV lifecycle based on Dorner et al. [10]. Plasmid vectors encoding the four main human HCV entry factors (4hEF)
CD81, SR-BI, CLDN1, and OCLN under the control of the mouse albumin promoter were used to create transgenic animals susceptible to HCVcc entry but not permissive to
robust viral replication. Crossing 4hEF mice with mice knock-out for deﬁned genes involved in innate immunity (Stat1/, Irf1/, Irf7/, Ifnar1/) resulted in transgenic
mice that can be efﬁciently infected by HCVcc. These mice were characterized by a viremia of approximately 2 months and circulating infectious virions with a TCID50 of
approximately 102/ml.
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alia by serum HCV RNA levels in mice lacking either IRF1,
IRF7, STAT1 or IFN-ab receptor was observed, demonstrating
that blunting deﬁned innate immune pathways allows to sus-
tain HCV replication in mouse hepatocytes in vivo (Fig. 1).
Serum HCV RNA levels up to 4.1 log10/ml were observed in
4hEF Stat1/ mice 60 days post HCVcc-inoculation and then
declined near to undetectability within 30 days. This decline
was likely due to HCV-speciﬁc adaptive immune responses, as
increased frequencies of B cells in the spleen and liver inﬁltra-
tion by IFN–c-producing CD8+ T cells were detected in 4hEF
Stat1/ mice. This indicates that HCV infection in innate immu-
nity-deﬁcient mice elicits adaptive immune responses contrib-
uting to viral clearance.
HCV replication and production of infectious viral particles
in HCVcc-infected transgenic mice was subsequently conﬁrmed
in vivo and in vitro. HCV proteins were visualized in livers of
transgenic mice expressing a blue ﬂuorescent protein TagBFP-
nlsMAVS fusion protein, which upon HCV NS3-4A protease
cleavage is translocated from the mitochondria membrane to
the nucleus. Nuclear TagBFP-nlsMAVS was observed in 0.2%
and 0.4% of mouse hepatocytes from 4hEF-TagBFP-nlsMAVS
and 4hEF-TagBFP-nlsMAVS Stat/mice, respectively. Moreover,
sera from STAT1-, IRF1-, IRF3-, IRF7-, IRF9- or MAVS-deﬁcient
mice collected 40 days after HCVcc infection were used to inoc-
ulate HuH7.5 cells. Inoculation with sera from STAT1-, IRF1-, and
IRF7-deﬁcient mice resulted in 1% of NS5A-positive cells,672 Journal of Hepatology 201demonstrating that indeed infectious viral particles were
released from the liver of these mice. Titration of the sera of
4hEF Stat1/ mice yielded a TCID50 of 2 log10/ml.
These inbred mice are the ﬁrst mice able to recapitulate the
HCV life cycle. This will open new perspectives for the study of
HCV and provide a platform for preclinical evaluation of antivi-
rals and vaccines. It will be interesting to see whether these par-
tially immunocompetent mice develop virus-induced liver
disease and liver cancer, which is the ultimate goal for a HCV
small animal model. Inbred mice also allow applying mouse
genetics to validate the role of deﬁned host factors in HCV infec-
tion. Furthermore, in contrast to human liver chimeric mice,
which are severely immunodeﬁcient, this mouse model for the
ﬁrst time allows to study adaptive immune responses to HCV
infection. Of note, viral loads are weaker in these transgenic mice
compared to humans or the human liver chimeric mouse models.
The decline in viraemia around 2 months post-infection may rep-
resent a limiting factor for assessing therapeutic vaccines. Fur-
thermore, the full picture of HCV-host interactions may only be
partially assessed in these mice engineered to have an impaired
innate immunity. The infection of animals with patient-derived
viral strains, which will be another important avenue to be devel-
oped in the future for vaccine development or studies of viral
pathogenesis. Taken together, the work of Dorner and colleagues
provides an important breakthrough in the ﬁeld and will open
new avenues to better understand HCV-host interactions and
the development of antivirals and vaccines.4 vol. 60 j 671–673
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